Skip to main content

Hit enter to search or ESC to close

VHIR

Menu

Uso de nanobodies para terapia dirigida contra células madre tumorales_RTC2019-006809-1

© 2024 VHIR Annual Report 2022.
Legal Advice | Data protection policy | Cookies policy

VHIR

Home
Facts & Figures
Top Stories
Highlights
eCORE
Partners and Acknowledgements
WIDER
Download Summary

VHIR Annual Report 2022